Identification of potential predictive markers of dexamethasone resistance in childhood acute lymphoblastic leukemia.
Ontology highlight
ABSTRACT: Response to dexamethasone (DEXA), as a hallmark drug in the treatment of childhood acute lymphoblastic leukemia (ALL), is one of the pivotal prognostic factors in the prediction of outcome in ALL. Identification of predictive markers of chemoresistance is beneficial to selecting of the best therapeutic protocol with the lowest effect adverse. Hence, we aimed to find drug targets using the 2DE/MS proteomics study of a DEXA-resistant cell line (REH) as a model for poor DEXA responding patients before and after drug treatment. Using the proteomic methods, three differentially expressed proteins were detected, including voltage dependent anion channel 1 (VDAC1), sorting Nexin 3 (SNX3), and prefoldin subunit 6 (PFDN6). We observed low expression of three proteins after DEXA treatment in REH cel
SUBMITTER: Dehghan-Nayeri N
PROVIDER: S-EPMC5440342 | biostudies-literature | 2017 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA